Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2018

View Archived Issues

MenoGeniX receives grant from NIA for drug to treat menopausal hot flashes

FDA grants fast track designation for PaxVax's chikungunya VLP vaccine

GAL-200-10 controls corneal neovascularization and fibrosis in vivo

DSMB gives another recommendation for phase III FOCUS trial

Astellas reports pipeline highlights of fourth quarter of fiscal 2017

Novel oral antibiotic DDS-01 presented for treating multidrug-resistant gonorrhoea infections

Cancer therapy driven by dopamine D2 receptor antagonism shows promise

Merck & Co. patents novel LXR-beta agonists

FDA approves Tafinlar with Mekinist for BRAF-positive anaplastic thyroid cancer

Isofol receives FDA feedback on SPA for pivotal study of arfolitixorin in colorectal cancer

Sage Therapeutics identifies GluN2A and/or GluN2B NAMs

Evolve doses first pediatric patient in phase III trial of PlasmaCap IG

FDA grants priority review to Tecentriq sBLA for first-line treatment of metastatic NSCLC

Lilly initiates phase III study of mirikizumab in moderate to severe plaque psoriasis

monARC Bionetworks begins strategic integration with Roivant drug development platform

Novel ELOVL4 gene mutation tied to spinocerebellar ataxia with retinitis pigmentosa

Charles River Laboratories extends collaboration with Michael J. Fox Foundation

ORR data from KEYNOTE-407 trial of Keytruda in first-line NSCLC support sBLA submission

New mutation in SLC20A2 gene found in Fahr's disease

FDA approves IND for female hair loss trial of Histogen's HSC-660

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...